Several factors appear to be related to the hepatic and/or metabolic response to exogenous leptin treatment, including the severity of metabolic disease at baseline, levels of triglycerides and triglyceride-rich apolipoproteins, baseline leptin levels, and changes in IGF-1 levels. The gene discussed is IGF1; the disease is metabolic disease.